FARE Statement on FDA Warning Letter

FARE Statement

FARE has issued the following statement following reports on CNBC about an FDA warning letter to Pfizer concerning epinephrine auto-injectors.

“The food allergy community relies on epinephrine auto-injector devices for quick, dependable administration of epinephrine, the only medication that can stop the symptoms of a severe reaction. The lives of children and adults with food allergies depend on them working precisely as they should, so anytime there are issues with an epinephrine auto-injector malfunctioning, we have serious concerns. At this time, we are waiting to learn more from the FDA and the manufacturer about the safety of these essential products.” - James R. Baker, Jr., MD, CEO and chief medical officer of Food Allergy Research & Education.

Media Contact
Nancy Gregory
Senior Director of Communications
Direct: 703-563-3066

For general inquiries, please call 800-929-4040.

About FARE

Food Allergy Research & Education (FARE) is the world’s leading food allergy advocacy organization and the largest private funder of food allergy research. Our mission is to improve the quality of life and the health of individuals with food allergies, and to provide them hope through the promise of new treatments. FARE is transforming the future of food allergy through innovative initiatives that will lead to increased awareness, new and improved treatments and prevention strategies, effective policies and legislation and novel approaches to managing the disease. For more information, please visit www.foodallergy.org. To join FARE’s transformative five-year fundraising and awareness campaign, Contains: Courage, supporting families living with food allergies and educating ALL communities about the disease, visit www.foodallergy.org/containscourage